Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Vical sued over pharmaceutical failure
Stock plunged on announcement that cancer-drug testing would cease
The San Diego law firm of Johnson & Weaver announced on November 1 that it is filing a lawsuit against San Diego biopharmaceutical firm Vical, Inc.
The suit, intended to be a class action, alleges that Vical touted the importance and potential success of Allovectin, a cancer drug, indicating that it would receive approval from the Food and Drug Administration.
On August 12 the company revealed that Allovectin failed to provide efficacious results and tests would be terminated. That day, the stock plunged to $1.53 from its price the previous trading day of $3.58; it closed on November 1 at $1.26.
The company will not comment on the suit.
Here's something you might be interested in.
Vical sued over pharmaceutical failure
Stock plunged on announcement that cancer-drug testing would cease
Vical sued over pharmaceutical failure
Stock plunged on announcement that cancer-drug testing would cease
The San Diego law firm of Johnson & Weaver announced on November 1 that it is filing a lawsuit against San Diego biopharmaceutical firm Vical, Inc.
The suit, intended to be a class action, alleges that Vical touted the importance and potential success of Allovectin, a cancer drug, indicating that it would receive approval from the Food and Drug Administration.
On August 12 the company revealed that Allovectin failed to provide efficacious results and tests would be terminated. That day, the stock plunged to $1.53 from its price the previous trading day of $3.58; it closed on November 1 at $1.26.
The company will not comment on the suit.
Comments